ARTICLE | Clinical News
Vandetanib regulatory update
September 27, 2010 7:00 AM UTC
FDA and the European Medicines Agency (EMA) accepted an NDA and MAA from AstraZeneca for vandetanib to treat advanced medullary thyroid cancer (MTC). FDA granted Priority Review to the NDA and set a P...